Maybe they do need our cpp??Andrew, Sarepta has already designed drugs that combine their PMOs with a cell-penetrating peptide. They call them PPMOs.
If you look at
Sarepta’s pipeline, it first lists their PMO drug candidates, followed by their PPMO drug candidates. The lead PPMO candidate is
about to complete a Phase 1 trial in DMD amenable to Exon 51 skipping (the indication for which eteplirsen was approved).
Phylogica believes it has better-performing CPPs. Hence last month’s “
400% Outperformance” announcement. I think you can be sure that the CPPs used for comparison in those animal studies (RXR4, PepK and Pip6a) would be well known to Sarepta.
(20min delay)